REPROCELL Signs Agreement to Prospectively Collect Samples for IFF's Microbiome Study | Business Upturn

REPROCELL Signs Agreement to Prospectively Collect Samples for IFF’s Microbiome Study


BELTSVILLE, Md., April 20, 2022 /PRNewswire/ — REPROCELL and IFF have entered into a clinical services agreement where in, REPROCELL will provide various types of samples for the study titled Isolation and Characterization of Multiple Microbial Species from Diverse Healthy Adults (IsoMic)”. The participants in the study will include donors of various ethnicities. Participant numbers are limited to a maximum of 10 from each of five ethnic group. In this study REPROCELL will first screen the donors and select the healthy donors that meet the study criteria such as BMI, healthy dietary intake profile, and between 18 to 50 years of age. Required samples from the donors meeting the criteria will be collected and provided to the scientists at IFF for microbiome analysis. The objectives of this study are to characterize the microbiome profile of this diverse cohort of healthy individuals from various sample types and to isolate microbial strains for possible future development as next generation probiotics.


“This study will help us strengthen our capabilities in microbiome research and our understanding of a healthy human microbiome profile,” said Ritesh Kumar, Ph.D., Research Investigator, IFF. “REPROCELL is pleased to be participating in this exciting prospective collection for IFF under our strict IRB and informed consent processes,” said Rama Modali, CEO, REPROCELL. 


About IFF’s Health & Biosciences division

Inspired by nature and distinguished by its world-class bioscience and microbiome capabilities, IFF’s Health & Biosciences division is a leading innovation partner for customers across a broad range of consumer product, industrial and agricultural sectors. IFF’s Health & Biosciences division works closely with our customers to enhance products – and their processes – to deliver safer, healthier, and more sustainable solutions.


REPROCELL provides services and reagents to support the entire drug discovery pathway. BioServe-brand biorepository and molecular services provide researchers with human tissue samples and services to support a wide variety of research and development, as well as provide a starting point for stem cell research. Stemgent-brand stem cell products and services, along with REPROCELL brand differentiated cells and reagents, enable researchers to bring the power of stem cells to bear on human disease. Alvetex-brand 3D culture products provide a physiologically relevant environment for cells that mimic the in vitro situation. Biopta-brand human tissue assays provide pharmaceutical companies with physiologically relevant information on human tissue prior to clinical trials. REPROCELL, founded in 2002, is based in Yokohama, Japan and has laboratories in Beltsville, MD, USA, Glasgow, UK and Hyderabad, India to support global research efforts.


For more information please visit or call 301-470-3362

Contact: Rama Modali, 3014703362, [email protected] 

Logo –

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Business Upturn takes no editorial responsibility for the same.